Roche's Actemra is already approved for three forms of arthritis.
CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year
Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.
Swedish researchers found rheumatoid arthritis patients tend to drop their first anti-TNF treatment.
Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.
The company expects to file an sNDA for plaque psoriasis next year.
Celgene is looking to market the $22,500-a-year-drug as a pre-biologic, which means jumping ahead of rivals like Enbrel and Humira.
Ten pharma companies will share money and biomarker research under an NIH collaboration.
Biogen Idec and JV partner Samsung are going into the biosimilars business.
Researchers say the drug class could be linked to a lower autoimmune risk among diabetics.
BMS is showing signs of emerging from the cliff, but doubt lingers on Eliquis's slow launch in a post-Plavix marketplace.
An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.
Sales may be rising, but a new study finds current psoriasis therapies leave room for improvement. Over half of patients said they want better options.
Analysts gave the infusion therapy a warm reception in RA, despite stiff competition in this category.
CHMP recommended two Remicade biosimilars for approval. Its nod comes with an added shakeup: the European agency sanctioned the copies for indications beyond RA.
The drug maker says it expects to use the Phase III clinical trial data to back applications in the EU and the US (when it gets a pathway setup).
Medscape asked and doctors shared what they hate about most medical apps, Livestrong merch hits the clearance rack, healthcare reform savings begin to surface, Lilly releases early RA drug trial results
A cocktail of older meds works as well as Enbrel, a study found, but docs are already comfortable with prescribing the biologic and aren't likely to switch therapies.
The actor and patient heads up a roundtable posted on the advocacy site CreakyJoints.
Sales slipped 9% during the quarter, compared to the same period last year, but analysts zeroed in on if and when the company will split and how arthritis pill Xeljanz will tackle Europe.
Humira led in sales and the company told analysts Pfizer's Xeljanz setback in Europe won't alter its RA future all that much.
European regulators said they're not satisfied that the information they have on hand is enough to let the drug go forward.
AstraZeneca cuts a deal with OCB to test unnamed cancer drug; an Enbrel biosimilar launches in India; BMS and Santaris seal an mRNA tech deal; Merck expands its China presence; Alzheimer's advocacy group parents a spin-off.
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.